enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. Type 2 diabetes drugs could lower dementia, Parkinson's ... - AOL

   www.aol.com/type-2-drugs-could-lower-133000670.html

   Some drugs used to treat type 2 diabetes could also help lower a person’s risk of neurodegenerative diseases, such as Alzheimer’s. Image credit: martin-dm/Getty Images. This article originally ...

3. Type 2 drugs could lower dementia, Parkison's disease risk - AOL

   www.aol.com/type-2-drugs-could-lower-133000359.html

   Researchers have found that people who take a type of type 2 diabetes drugs SGLT2 inhibitors have a significantly lower risk of dementia, overall, and of Alzheimer's disease and Parkinson's, in ...

4. These Diabetes Drugs Could Help Lower Your Risk of ... - AOL

   www.aol.com/diabetes-drugs-could-help-lower...

   SGLT2 inhibitors lowered dementia, Parkinson’s risk by 22% For this study, the researchers accessed data from 358,862 participants with type 2 diabetes and followed them for an average of 9.6 years.

5. Donepezil - Wikipedia

   en.wikipedia.org/wiki/Donepezil

   Donepezil, sold under the brand name Aricept among others, is a medication used to treat dementia of the Alzheimer's type. [3] [4] [8] It appears to result in a small benefit in mental function and ability to function. [9] Use, however, has not been shown to change the progression of the disease. [10] Treatment should be stopped if no benefit ...

6. Management of Parkinson's disease - Wikipedia

   en.wikipedia.org/wiki/Management_of_Parkinson's...

   In the management of Parkinson's disease, due to the chronic nature of Parkinson's disease (PD), a broad-based program is needed that includes patient and family education, support-group services, general wellness maintenance, exercise, and nutrition. At present, no cure for the disease is known, but medications or surgery can provide relief ...

7. Cholinesterase inhibitor - Wikipedia

   en.wikipedia.org/wiki/Cholinesterase_inhibitor

   They are generally used to treat Alzheimer's disease and dementia. [6] If a benefit occurs, it is generally during the second or third month after starting. [6] It is difficult to determine which ChEI has greater efficacy, due to design flaws in head-to-head comparison studies. [11] Pyridostigmine is used in the treatment of myasthenia gravis. [12]